Theremia Health

Theremia is a pioneering health tech company transforming drug development through advanced AI technologies, with a specialized focus on central nervous system (CNS) disorders including neurology and psychiatry. The company has developed a proprietary AI platform that optimizes drug derivatives for specific patient subgroups by predicting treatment efficacy and adverse effects at the individual level. Theremia's core innovation is the Nearest Neighbor Pairing method — a causal machine learning approach that matches treated patients to the most similar control patients based on observed variables, enabling more precise estimation of individual treatment effects than the traditional Win Ratio method. This approach is designed to improve benefit-risk assessment in CNS clinical trials, addressing the critical challenge that 60% of CNS patients do not adhere to their treatments due to lack of efficacy or adverse effects. The company works at the intersection of AI, data science, and pharma, partnering with pharmaceutical companies to identify optimal patient populations and refine clinical trial endpoints before Phase I. Theremia is a Entrepreneur First alumni, France 2030 Grand Challenge laureate, and was selected for the Google for Startups Gemini Startup Forum.